Literature DB >> 1985750

Combination therapy for anaplastic giant cell thyroid carcinoma.

M Schlumberger1, C Parmentier, M J Delisle, J E Couette, J P Droz, D Sarrazin.   

Abstract

Since 1981, 20 patients with anaplastic giant cell carcinoma of the thyroid have been prospectively treated according to a combination regimen of chemotherapy and external beam radiation therapy. Two types of chemotherapy were used every 4 weeks, depending on the patient's age. For those younger than 65 years, a combination of doxorubicin (60 mg/m2) and cisplatin (90 mg/m2) was given, and for older patients mitoxantrone (14 mg/m2) was used. Radiotherapy was carried out between Day 10 and Day 20 of the first four cycles of chemotherapy. It delivered 17.5 Gy in 7 fractions to the neck and the superior mediastinum. Survival exceeding 20 months was observed in three patients. Complete neck tumor response was observed in five patients, among whom four had undergone previous operations. No response was seen in distant metastases, which were the cause of death in 14 patients. These treatment modalities are effective in some patients, both in terms of survival and of local control, avoiding death from local invasion. Gross tumor resection should be performed whenever possible but should not delay the commencement of this protocol. Toxicity was high and remains the main limiting factor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985750     DOI: 10.1002/1097-0142(19910201)67:3<564::aid-cncr2820670306>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

Review 1.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Authors:  W Voigt; T Kegel; M Weiss; T Mueller; H Simon; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Anaplastic thyroid cancer and hyperthyroidism.

Authors:  Vijay Kumar; Bruno Blanchon; Xin Gu; Marjorie Fowler; David Scarborough; Cherie Ann Nathan; Subhashini Yaturu
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

5.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

Review 8.  Anaplastic thyroid carcinoma: an overview.

Authors:  Wendy R Cornett; Anand K Sharma; Terry A Day; Mary S Richardson; Rana S Hoda; Jon A van Heerden; Jyotika K Fernandes
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

Review 9.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Role of surgeons in clinical trials for thyroid cancer.

Authors:  Y Nancy You; Samuel A Wells
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.